Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 8/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253658 | 0.98 | CES2 (0.43) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL12807256 | 0.97 | CES2 (0.46) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL15259279 | 0.97 | CES2 (0.46) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL13226771 | 0.97 | CES2 (0.46) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL16350546 | 0.92 | CES2 (0.50) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL23937750 | 0.90 | MEN1 (0.39) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL11928874 | 0.90 | ALDH1A1 (0.41) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL12733551 | 0.90 | ALDH1A1 (0.41) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL13007897 | 0.88 | MEN1 (0.40) | CES2MEN1KMT2AFAAHTSHR | |
| SCHEMBL12353672 | 0.88 | MEN1 (0.40) | CES2MEN1KMT2AFAAHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100233082-A1 | 68GA-Labeled Peptide-Based Radiopharmaceuticals | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233082-A1 | 68GA-Labeled Peptide-Based Radiopharmaceuticals | ITGAV, ITGB3, GRPR | CES2 4590/4885MEN1 716/4885KMT2A 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.